Citrulline Antibody, Clone 2D3.1: ATTO 390

Citrulline is a non-essential, non-proteinogenic amino acid that plays a central role in the urea cycle and nitric oxide (NO) metabolism. In the brain, citrulline is produced as a byproduct of nitric oxide synthase (NOS) activity, particularly neuronal NOS (nNOS), which converts arginine into NO and citrulline. This positions citrulline as both a biomarker and a functional participant in NO signaling—a pathway critical for synaptic plasticity, neurovascular regulation, and memory formation. In neurodegenerative disease contexts, citrulline has garnered attention for its antioxidant and neuroprotective properties. It enhances NO bioavailability without promoting the formation of reactive nitrogen species, thereby supporting cerebral blood flow and reducing oxidative stress. Supplementation with citrulline has been shown to improve cognitive performance in aging models, likely through improved mitochondrial function and reduced neuroinflammation. Citrulline also contributes to ammonia detoxification and may help mitigate excitotoxicity, a key driver of neuronal injury in conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS) . Its ability to modulate metabolic and redox homeostasis makes it a promising candidate for therapeutic development. As a naturally occurring compound with favorable safety and pharmacokinetic profiles, citrulline represents a compelling target for interventions aimed at preserving cognitive function and slowing neurodegenerative progression.

L-Citrulline, 2-Amino-5- (carbamoylamino) pentanoic acid, Citrulline, Citrulline-modified protein, ACPA, Anti-citrullinated protein antibodies, Anti-citrullinated protein, Modified Citrulline, Citrulline-containing protein, Citrullinated protein

A 1:1000 dilution of SMC-500 was sufficient for detection of Citrulline in 2 µg of Citrulline conjugated to BSA by ECL immunoblot analysis using Goat Anti-Mouse IgG:HRP as the secondary Antibody.